Disease Progression in Women With X-linked Adrenoleukodystrophy
NCT06178120 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2024-01-31
Summary
Observational, single-site prospective and minimally interventional study in women with X-linked adrenoleukodystrophy (ALD), conducted in France.
Conditions
- X-linked Adrenoleukodystrophy
Sponsors & Collaborators
-
Minoryx Therapeutics, S.L.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-01-02
- Primary Completion
- 2026-12-31
- Completion
- 2027-06-30
Countries
- France
Study Locations
More Related Trials
-
Clinical Evaluation of Patients With X-linked Retinoschisis
NCT02331173 ·Status: COMPLETED
-
Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)
NCT01433354 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Natural History Study of ENPP1 Deficiency and the Early-onset Form of ABCC6 Deficiency
NCT05050669 ·Status: COMPLETED
-
Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients
NCT00718341 ·Status: COMPLETED ·Phase: PHASE2
-
Angelman Syndrome Natural History Study-FAST UK
NCT05100810 ·Status: RECRUITING
-
Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome
NCT01357239 ·Status: COMPLETED ·Phase: PHASE2
-
Neural Biomarkers in Fragile X Syndrome
NCT06957054 ·Status: COMPLETED
-
A Study of RO4917523 in Patients With Fragile X Syndrome
NCT01517698 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome
NCT01253629 ·Status: COMPLETED ·Phase: PHASE2
-
An Open Label Extension Study in Subjects With Fragile X Syndrome
NCT01555333 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome
NCT01325740 ·Status: SUSPENDED ·Phase: PHASE2
-
Antioxidant Signature in Adult Patients With Phenylketonuria
NCT02212288 ·Status: COMPLETED
-
Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)
NCT03333447 ·Status: COMPLETED
-
An Initial Study of AZD7325 in Adults With Fragile X Syndrome
NCT03140813 ·Status: COMPLETED ·Phase: PHASE1
-
Study of the Pathophysiology of RNU4ATAC and RTTN Associated Syndromes
NCT06111950 ·Status: RECRUITING ·Phase: NA
-
Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS
NCT03802799 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3
-
The Primordial Dwarfisms: Diagnosis, Identification of the Molecular Basis of Seckel Syndrome and Microcephalic Osteodysplastic Primordial Dwarfism Type II
NCT03139903 ·Status: COMPLETED
-
A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During Pregnancy
NCT04998812 ·Status: COMPLETED ·Phase: PHASE4
-
Understanding the Spectrum of ENPP1 Deficiency and Acute ABCC6 Deficiency
NCT04372446 ·Status: COMPLETED
-
Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder
NCT06261060 ·Status: RECRUITING ·Phase: PHASE2
-
Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)
NCT03349242 ·Status: COMPLETED
-
Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
NCT05710692 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
NCT03018730 ·Status: COMPLETED ·Phase: PHASE3
-
A Study With RO4917523 in Patients With Fragile X Syndrome
NCT01015430 ·Status: COMPLETED ·Phase: PHASE2
-
Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease
NCT03566017 ·Status: COMPLETED ·Phase: PHASE3